Data-Driven Medicine Best Bet For Patient & Research Outcomes

Driving Medicine Forward

When SOPHiA GENETICS, a healthcare technology company focused on data-driven medicine for life sciences research and listed among the 50 Smartest Companies by the MIT Technology Review, went public (Nasdaq: SOPH) on July 22nd of this year with a valuation at IPO of $1.1 billion, it was yet another indication of where deep tech startups with an excellent IP are heading. This was after the company had raised some of $250 million in funding over seven rounds since it was founded back in 2011 by Jurgi Camblong, Lars Steinmetz and Pierre Hutter.

Whether through a special purpose acquisition company (SPAC), via the more traditional route of simply being acquired by a public company with boatloads of cash, SOPHiA GENETICS — along with Babylon Health and Recursion Pharmaceuticals — is a barometer of a shifting landscape, one with an honest appreciation of deep tech’s profound influence in the biotechnology and healthcare industries.


In SOPHiA GENETICS’ case, it’s all about Data-Driven Medicine, made possible through its proprietary SOPHiA DDM™ product, a cloud-based Software-as-a-Service (SaaS) platform that can analyze data from multiple modalities and scale globally to support data-driven medicine adoption for:

• Genomics, ultimately to increase productivity, enabling high-throughput genomic analysis for cancers and inherited diseases

• Radiomics, providing streamlined, end-to-end, automated workflows to segment medical images, extract standardized radionics features and correlate them with outcomes

• Multimodal, harnesses the power of advanced AI and machine learning (ML) models, enabling the analysis of clinical, biological, genomics and radionics data

Democratizing data-driven medicine


Working with customers from nearly 800 institutions in over 70 countries, SOPHiA GENETICS’ network is pushing forward data-driven medicine to improve health outcomes and economics worldwide.

None of this would have happened if it wasn’t for the founding team, though.

The co-Founder and CEO is Dr. Jurgi Camblong, a visionary entrepreneur who is pioneering the data-driven medicine movement.

A molecular biologist (published in Cell, Science and Nature), Camblong obtained a Ph.D. in Life Sciences from the University of Geneva and an EMBA in the Management of Technology from EPFL/HEC Lausanne.

Of note too is that Camblong has been a member of the Advisory Council on Digital Transformation to the Swiss government and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.

Dr. Pierre Hutter, a former CSO and Co-founder of Sophia Genetics and former Head of Genetics Service, HVS, Switzerland, is one of the most renowned medical geneticists in Switzerland who discovered the landmark speciation gene Hmr (Hybrid male rescue) in Drosophila, which has become the most studied gene in the field of reproductive isolation.

Between 2005 and 2011 he was co-director of the Geneva University laboratory of Predictive Oncology, one of the two reference laboratories for the study of cancer predisposition. As head of the Medical Genetics Service of the Valais hospital, Hutter was involved in the development of genetic diagnoses based on high-throughput sequencing, worked as a consultant for a private laboratory, and is an expert in the accreditation of molecular genetics laboratories. He represents the Swiss Society of Medical Genetics at the FAMH commission of the Swiss Academy of Medical Sciences.

Hutter obtained a Ph.D. in Genetics from the University of Edinburgh and postdoctoral work at the University of Cambridge.

Lars Steinmetz, a Professor of Genetics at Stanford University School of Medicine and Co-Director, Stanford Genome Technology Center, Group Leader, Senior Scientist, EMBL, Germany, is SOPHiA GENETICS final Co-Founder and President of its Scientific Advisory Board.

Steinmetz studied Molecular Biophysics and Biochemistry at Yale University and conducted his Ph.D. research on genome-wide approaches to study gene function and natural phenotypic diversity at Stanford University.

As far as research goes, his lab develops and applies cutting-edge technologies to investigate the function and mechanism of transcription, the genetic basis of complex phenotypes and the genetic and molecular systems underpinning disease. Their ultimate goal is to enable the development of personalized, preventative medicine.

“Since inception, we knew that leveraging a wide range of data modalities powered by cutting-edge technologies was key to sustainably deliver better outcomes to the global healthcare community.”

 — Jurgi Camblong, CEO and Founder at SOPHiA GENETICS

“Sustainably deliver better outcomes”, that’s what it’s all about. And Camblong, together with his executive team, board and key scientific personnel, spurred on by a shared passion “for delivering innovative healthcare solutions for all”, puts SOPHiA GENETICS in a very good position on the Data-Driven Medicine market.